The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

China Medical University

Status

Enrolling

Conditions

Breast Cancer

Treatments

Drug: Standard Therapy

Study type

Observational

Funder types

Other

Identifiers

NCT05263570

HR-HER2-RWS-01

Details and patient eligibility

About

To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.

Full description

This study collected patients used standard neoadjuvant therapy (TCbHP/THP/EC-THP/AC-THP) among stage II-III HR+/HER2+ early breast cancer, and to describe patient clinical characteristics and clinical outcomes of them in real world settings.

Enrollment

200 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 years or older
HR+/HER2- breast cancer diagnosis based on local standards
Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time
Standard Therapy, determined at the discretion of the investigator, including （TCbHP/THP/EC-THP/AC-THP）
Complete medical history was available
Karnofsky Performance Status (KPS) Scale score ≥ 70

Exclusion criteria

Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy)
Pregnant or breast-feeding women
Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer
Those who have stage IV breast cancer